Washington, D.C. partner and co-chair of the IP Group Bob Stoll spoke at the Biotech/Chemical Partnership meeting hosted and organized by the USPTO on their campus on April 7, 2015. 

Bob spoke on the importance of improvements to the quality of patents as an alternative to restrictive patent subject matter eligibility and patent litigation reform. He focused on best practices for written description, enablement, obviousness and application drafting.  About 75 practitioners were in attendance and many more viewed the webinar feed from the forum.

Source: USPTO BCP Meeting